<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212598</url>
  </required_header>
  <id_info>
    <org_study_id>Immune consolidation therapy</org_study_id>
    <nct_id>NCT04212598</nct_id>
  </id_info>
  <brief_title>The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer</brief_title>
  <official_title>The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma, an Open, Prospective, Single-arm Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophageal cancer is a kind of disease with high incidence and mortality. Definitive&#xD;
      concurrent chemoradiotherapy is an important treatment for locally advanced esophageal&#xD;
      squamous cell carcinoma. To Investigate the value of immunotherapy consolidation in locally&#xD;
      advanced esophageal squamous cell carcinoma after completing radical concurrent&#xD;
      chemoradiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In East countries, especially China, more than 75 percent of esophageal cancers are primary&#xD;
      squamous cell cancers located in the middle and upper thoracic segments, whereas&#xD;
      adenocarcinoma accounted for less than 20 percent.Unlike other malignancies, more than half&#xD;
      of esophageal cancer were diagnosed as locally advanced at the time of diagnosis. Definitive&#xD;
      concurrent chemoradiotherapy is an important treatment for locally advanced esophageal&#xD;
      squamous cell carcinoma.&#xD;
&#xD;
      Immune checkpoint inhibitors are a new class of antitumor drugs. They are different from&#xD;
      traditional cytotoxic chemotherapy drugs and can target the regulatory molecules that play an&#xD;
      inhibitory role in the tumor immune system.&#xD;
&#xD;
      Recent clinical studies had shown that for locally advanced non-small cell lung cancer,&#xD;
      maintenance therapy with the immune checkpoint inhibitor could significantly improve the&#xD;
      overall survival for locally advanced non-small cell lung cancer after definitive concurrent&#xD;
      chemoradiotherapy. Moreover, the immune checkpoint inhibitor PD-1 has also been shown to be a&#xD;
      promising anticancer agent in esophageal cancers. Therefore, the present study intended to&#xD;
      give a standard dose (50.4Gy/28F) to locally advanced esophageal squamous cell carcinoma for&#xD;
      radical chemoradiotherapy, and than to give the Sintilimab as consolidation therapy for 1&#xD;
      year after completion of radiotherapy. At the time point of 6 weeks after radiotherapy, all&#xD;
      participates need a full evaluation of the treatment response. In patients with residual&#xD;
      disease, we would give them an additional radiotherapy boost to 61.2 Gy/34F under the&#xD;
      guidance of PET-CT or ultrasound endoscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">January 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 4, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single arm phase II study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with disease progression within 2 years after treatment</measure>
    <time_frame>2-years</time_frame>
    <description>Progression-free survival is measured from the date of enrolling to the date of disease progression or death from any cause or final follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who died within 2 years after treatment</measure>
    <time_frame>2-years</time_frame>
    <description>Progression-free survival is measured from the date of enrolling to the date of death from any cause or final follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The number of patients with treatment-related toxicity between the treatment period and half a year after treatment</measure>
    <time_frame>0.5-year</time_frame>
    <description>Acute toxicities were scored according to the Common Toxicity Criteria for Adverse Events, version 3.0 (National Cancer Institute, NCI, Rockville, MD).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Definitive concurrent chemoradiotherapy or radiotherapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.</description>
    <arm_group_label>Definitive concurrent chemoradiotherapy or radiotherapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG 0-1; Life expectancy &gt;6 months;&#xD;
&#xD;
          -  Stage II/III esophageal cancer;&#xD;
&#xD;
          -  Pathology confirmed squamous cell carcinoma;&#xD;
&#xD;
          -  Hemoglobin ≥10g/dl, WBC ≥3.0 x 109/L, platelet ≥100 x 109/L; CR≤ 1.0x normal upper&#xD;
             limit, total bilirubin ≤ 1.5x normal upper limit, AST and ALT≤ 1.5x normal upper&#xD;
             limit, AKP≤ 2.5x normal upper limit;&#xD;
&#xD;
          -  Have a full understanding of this study, participate voluntarily, have follow-up&#xD;
             conditions and sign the informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage IV esophageal cancer;&#xD;
&#xD;
          -  Esophageal adenocarcinoma;&#xD;
&#xD;
          -  Gastric esophageal junction adenocarcinoma;&#xD;
&#xD;
          -  ECOG &gt; 2;&#xD;
&#xD;
          -  Progression after first-course radiotherapy;&#xD;
&#xD;
          -  Existing active infection, such as active tuberculosis, hepatitis, etc.;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Conghua Xie, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Conghua Xie, MD</last_name>
    <phone>02767812510</phone>
    <phone_ext>86</phone_ext>
    <email>chxie_65@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Yu, MD</last_name>
    <phone>02767812539</phone>
    <phone_ext>86</phone_ext>
    <email>yujingrt@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conghua Xie, Dr</last_name>
      <phone>0086-27-67812607</phone>
      <email>chxie_65@whu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jing Yu, Dr</last_name>
      <phone>0086-27-67812539</phone>
      <email>yujingrt@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Conghua Xie, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Yu, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.</citation>
    <PMID>28055103</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999 May 5;281(17):1623-7.</citation>
    <PMID>10235156</PMID>
  </reference>
  <reference>
    <citation>Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1;20(5):1167-74.</citation>
    <PMID>11870157</PMID>
  </reference>
  <reference>
    <citation>Suh YG, Lee IJ, Koom WS, Cha J, Lee JY, Kim SK, Lee CG. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer. Jpn J Clin Oncol. 2014 Jun;44(6):534-40. doi: 10.1093/jjco/hyu047. Epub 2014 Apr 24.</citation>
    <PMID>24771865</PMID>
  </reference>
  <reference>
    <citation>Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):656-64.</citation>
    <PMID>15708243</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 21, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2019</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan University</investigator_affiliation>
    <investigator_full_name>Conghua Xie,MD,PhD</investigator_full_name>
    <investigator_title>Director, Head of Radiation and Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Esophageal Squamous Cell Carcinoma</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

